key: cord-0852777-ea778slg
authors: Cholankeril, George; Podboy, Alexander; Aivaliotis, Vasiliki Irene; Tarlow, Branden; Pham, Edward A.; Spencer, Sean; Kim, Donghee; Hsing, Ann; Ahmed, Aijaz
title: High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California
date: 2020-04-10
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.04.008
sha: d5880a14b5114d4a0f495b082a83ac3aab09f055
doc_id: 852777
cord_uid: ea778slg

nan

The current pandemic caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), continues to spread, and as of April 1, 2020, over 920,000 cases have been reported worldwide. 1 While the respiratory complications of SARS-CoV-2 have been described, the impact on the gastrointestinal and hepatic systems remains unknown, with conflicting levels noted in preliminary cases from China and Singapore. [2] [3] [4] We aim to characterize the gastrointestinal manifestations in patients with SARS-CoV-2 at our institution.

We performed a retrospective analysis on data collected from consecutive patients who presented to our institution between March 04, 2020, and March 24, 2020. All patients had confirmed SARS-CoV-2 infection based on a positive polymerase chain reaction testing. An expedited approval from our Institutional Review Board was obtained. In addition to the symptoms reported by the patients at presentation, demographic, clinical and laboratory data were evaluated. Frequencies of categorical variables and the means ± standard deviation (SD) or median (interquartile range [IQR]) of the continuous variables were calculated. Data were collected and analyzed using SAS 9.4 (Charlotte, NC).

A total of 116 patients with confirmed SARS-CoV-2 were identified. Clinical characteristics and demographic data are described in Table 1 . Overall, the median age was 50 years [IQR, 35-67] with a higher distribution of males (53.4%) and Caucasians (50.9%). 27.9% were noted to have a BMI > 30. 11.6% of patients were noted to be healthcare practitioners or allied staff.

The most common symptoms at presentation included cough (94.8%), fever (76.7%), dyspnea (58%), and myalgias (52.2%). The median duration of these respiratory symptoms was 5.0 [IQR, [3] [4] [5] [6] [7] days. With regards to admission status, 83 patients (71.6%) were evaluated in the emergency room or clinic only, 24 (20.7%) were admitted to the general medical floor, and 9 (7.8%) were admitted to the intensive care unit (ICU). The average length of stay for patients only admitted to the general floor was 5.0 days (SD, 3.9) vs 10.5 days (SD, 0.5) for patients that required ICU level care. 5 patients were still hospitalized at the time of this report and one patient died at hospital day 11.

Gastrointestinal symptoms were reported by 31.9% of patients, with 89.2% describing their gastrointestinal complaints as mild ( Table 1) 65 patients underwent laboratory testing that included liver enzymes and total bilirubin levels at presentation; with 26 patients (40%) demonstrating hepatic dysfunction. 22 of the 26 patients with liver enzyme elevations were noted to have baseline liver enzymes that were within normal limits. All four patients with baseline abnormalities in liver enzymes were noted to have at least a two-fold elevation in liver enzymes during their SARS-CoV-2 disease course. Among those with abnormalities in liver chemistries, we noted slightly higher levels of aspartate aminotransferase (AST) compared to alanine aminotransferase (ALT) as shown in Table 1 Isolated AST involvement can potentially indicate a non-hepatic etiology, however autopsy reports of a patient with severe SARS-CoV-2 infection revealed moderate microvesicular steatosis with mild lobular and portal inflammatory activity suggestive of direct viral injury within the liver, compared to only minimal interstitial mononuclear inflammatory infiltrates in cardiac biopsies. 5 Additionally, in a sub-analysis of our data, 43 patients were screened for cardiac injury with troponin I or T enzyme levels, and only 3 were noted to have positive cardiac biomarkers. Interestingly, 2/3 of these patients were noted to have normal AST values.

There are several limitations to our analysis. This is a single institution study leading to the possibility of regional bias, and caution is needed prior to generalizing our experience.

However, according to public health reports over our study period, a total of 364 cases of SARS-CoV-2 were identified in our county (Santa Clara County, CA), and the 116 patients at our institution represent over 30% of the total reported cases, potentially aiding the generalizability of our observations. 13 Also, the decision to obtain liver function tests was not controlled, leading to the potential for recall bias. As evaluation of SARS-COV2 at our hospital was streamlined, exhaustive documentation of non-respiratory symptoms may be incomplete. Moreover, testing was currently only offered under specific criteria (that required pulmonary symptoms) and could have missed patients with gastrointestinal symptoms only, thereby underestimating the true prevalence of gastrointestinal involvement. It is also unclear if our results can be extrapolated to asymptomatic or minimally symptomatic patients that do not seek medical care.

In summary, our results add to the growing body of literature that note a significant proportion of concurrent gastrointestinal manifestations related to the SARS-CoV-2. Elevation in AST levels was the lone variable correlated to disease activity. 

Coronavirus disease 2019 (COVID-19) Situation Report -71

Clinical characteristics of 2019 novel coronavirus infection in China

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol

Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes

We would like to thank our program director, David Limsui, for his tireless dedication to our medical education and to all the front line healthcare workers across the globe combatting the current pandemic.